Related Experiment Video

Updated: Apr 29, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.4K

Systemic Therapy for Merkel Cell Carcinoma: What's on the Horizon?

Guilherme Rabinowits1

  • 1Dana-Farber Cancer Institute, Harvard Medical School, Department of Medical Oncology, Center for Head and Neck Oncology, 450 Brookline Avenue, Boston, MA 02215, USA. guilherme_rabinowits@dfci.harvard.edu.

Cancers
|May 21, 2014
PubMed

Insights

Merkel cell carcinoma, a rare and aggressive skin cancer, is increasing in incidence. Novel targeted therapies, especially immunotherapy, offer new hope for this lethal malignancy.

Area of Science:

  • Oncology
  • Dermatology
  • Immunology

Background:

  • Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer primarily affecting elderly individuals.
  • MCC incidence is rising due to improved diagnostics, increased awareness, and an aging population.
  • This malignancy has a poor prognosis, with a five-year survival rate around 50%.

Purpose of the Study:

  • To review novel targeted therapies for Merkel cell carcinoma.
  • To discuss the role of immunotherapy in MCC treatment.
  • To highlight ongoing clinical trials for advanced MCC.

Main Methods:

  • Literature review of recent advancements in MCC targeted therapy.
  • Analysis of current research on immunotherapy agents.
  • Overview of active clinical trials investigating novel treatments.

Main Results:

  • Emerging targeted therapies show promise in preclinical and early clinical studies.
  • Immunotherapy, particularly checkpoint inhibitors, has demonstrated significant efficacy in MCC.
  • Several novel therapeutic strategies are under active investigation in ongoing trials.

Conclusions:

  • A deeper understanding of MCC molecular pathways fuels optimism for new treatments.
  • Targeted therapies and immunotherapy represent a paradigm shift in MCC management.
  • Continued research and clinical trials are crucial for improving patient outcomes.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

19.9K
A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

18.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K